ALDA Pharmaceuticals Corporation Enters Into Vendor Agreement With London Drugs Limited

VANCOUVER, BRITISH COLUMBIA--(Marketwire - October 05, 2009) - ALDA Pharmaceuticals Corp. (TSX VENTURE: APH)(OTCBB: APCSF) (“the Company” or “ALDA”) announces that it has entered into a Vendor Agreement with London Drugs Limited and the first order has been shipped. ALDA’s products will be distributed through 70 stores operated by London Drugs in all four Western provinces. Dr Terrance Owen, President & CEO states, “This agreement with London Drugs is a very important step in achieving distribution of our products to consumers. Their stores draw huge numbers of customers every day and this traffic will give ALDA’s products a tremendous boost. As the flu season and the H1N1 pandemic approach, ALDA and London Drugs will be in the forefront helping to keep people healthy.”

About London Drugs (www.londondrugs.com)

London Drugs began its pharmacy business in Vancouver in 1945. Over the years, new departments were added, including cameras, small appliances, consumer electronics, computing equipment and software, pharmaceutical counseling, cosmetics, groceries, insurance and travel services. London Drugs now has 70 stores located in British Columbia, Alberta, Saskatchewan, and Manitoba with more than 6000 staff.

About ALDA Pharmaceuticals Corp. (www.aldacorp.com)

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCBB under the symbol APCSF.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA’s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as “outlook”, “will”, “could”, “would”, “might”, “remains”, “to be”, “plans”, “believes”, “may”, “expects”, “intends”, “anticipates”, “estimate”, “future”, “plan”, “positioned”, “potential”, “project”, “remain”, “scheduled”, “set to”, “subject to”, “upcoming”, and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.


Contacts:
ALDA Pharmaceuticals Corp.
Sales Management:
Diane Mann, Account Executive
Office: 604-521-8300 Ext. 4 or Cell: 604-657-0369
diane_mann@aldacorp.com

ALDA Pharmaceuticals Corp.
Sales Management:
Adriana Cikojevic, Account Manager
Office: 604-521-8300 Ext. 4
adriana_cikojevic@aldacorp.com

ALDA Pharmaceuticals Corp.
Sales Management:
Tracy Haubrich, Account Manager
Office: 604-521-8300 Ext. 4
tracy_haubrich@aldacorp.com

London Drugs
Retail Sales
(http://www.londondrugs.com/Cultures/en-US/StoreLocator.htm)

Eastern Esthetics (ON, QU, NB, NS, PE, NL)
Retail Sales
902-450-2161

LCN Canada - West (MB, SK, AB, BC, NW, YK)
Retail Sales
780-462-2580

ALDA Pharmaceuticals Corp.
Scott Young
Investor Relations
604-377-5781
scott_young@aldacorp.com
www.aldacorp.com

MORE ON THIS TOPIC